Elevated Urine Heparanase Levels Are Associated with Proteinuria and Decreased Renal Allograft Function

Itay Shafat1, Amir Agbaria2, Mona Boaz3, Doron Schwartz2, Ronny Baruch2, Richard Nakash4, Neta Ilan1, Israel Vlodavsky1*, Talia Weinstein2*

1 Cancer and Vascular Biology Research Center, the Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel, 2 Department of Nephrology, Tel Aviv Medical Center, Tel Aviv, Israel, 3 Epidemiology Unit, E. Wolfson Medical Center, Holon, Israel, 4 Transplant Clinic, Tel Aviv Medical Center, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel

Abstract

Heparanase is an endo-β-glucuronidase that cleaves heparan sulfate side chains, leading to structural modifications that loosen the extracellular matrix barrier and associated with tumor metastasis, inflammation and angiogenesis. In addition, the highly sulfated heparan sulfate proteoglycans are important constituents of the glomerular basement membrane and its permselective properties. Recent studies suggest a role for heparanase in several experimental and human glomerular diseases associated with proteinuria such as diabetes, minimal change disease, and membranous nephropathy. Here, we quantified blood and urine heparanase levels in renal transplant recipients and patients with chronic kidney disease (CKD), and assessed whether alterations in heparanase levels correlate with proteinuria and renal function. We report that in transplanted patients, urinary heparanase was markedly elevated, inversely associated with estimated glomerular filtration rate (eGFR), suggesting a relationship between heparanase and graft function. In CKD patients, urinary heparanase was markedly elevated and associated with proteinuria, but not with eGFR. In addition, urinary heparanase correlated significantly with plasma heparanase in transplanted patients. Such a systemic spread of heparanase may lead to damage of cells and tissues alongside the kidney. The newly described association between heparanase, proteinuria and decreased renal function is expected to pave the way for new therapeutic options aimed at attenuating chronic renal allograft nephropathy, leading to improved graft survival and patient outcome.

Introduction

The glomerular capillary barrier exerts both size- and charge-selective properties [1]. The charge-selective feature is attributed primarily to highly sulfated proteoglycans which reside in the glomerular basement membrane (GBM), podocytes, and the glomerular endothelium [2,3]. Of particular significance are heparan sulfate (HS) proteoglycans (HSPGs), consisting of a core protein to which glycosaminoglycan HS chains are attached and held, among other factors, responsible for the permselective properties of the glomerular capillary wall. Loss of HSPGs was observed in several experimental and human glomerulopathies, including diabetic nephropathy, minimal change disease, and membranous glomerulopathy [4,5], where a decrease in HS inversely correlates with proteinuria [6–9]. Accordingly, administration of monoclonal anti-HS antibody resulted in massive proteinuria in a rat model [10], and removal of HS by enzymatic cleavage resulted in increased GBM permeability [6], supporting a contribution of HS to glomerular permselectivity. Decreased content of HS has been noted in the glomerular barrier in a variety of human and experimental proteinuric diseases, attributed, in part, to over-expression of heparanase [5,11–16].

Heparanase is an endo-β-glucuronidase that cleaves HS side chains of HSPGs presumably at sites of low sulfation, leading to disassembly of the ECM and BM, thereby affecting fundamental biological phenomena associated with cell motility and tissue remodeling [17–20]. Expression of heparanase, the only mammalian endoglycosidase that degrades HS chains, was upregulated in animal models of proteinuric renal disease including passive Heymann nephritis [21], puromycin nephrosis [14], anti-GBM nephritis [22], and adriamycin nephropathy [23], likely damaging the permselective properties of HS. Indeed, over-expression of heparanase in transgenic mice leads to proteinuria [24], while treatment with a polyclonal anti-heparanase antibody resulted in a 3-fold reduction of proteinuria in a model of anti-GBM disease [22]. Similarly, PI-88, a sulfated oligosaccharide inhibitor of heparanase, significantly reduced the loss of glomerular HSPGs and the associated proteinuria [13], further emphasizing the involvement of heparanase in the development of proteinuria.

Since heparanase activity is associated with a loss of glomerular HS and consequent proteinuria, the present study was undertaken to determine plasma and urine heparanase levels in renal transplant recipients and chronic kidney disease (CKD) patients...
and to assess whether alterations in heparanase levels correlate with proteinuria and kidney function. We report that urinary heparanase is markedly elevated in patients with CKD and following kidney transplantation. Notably, urine heparanase was significantly associated with proteinuria and inversely associated with estimated glomerular filtration rate (eGFR) in transplanted patients. A highly significant association was found between urine and plasma heparanase levels in transplanted patients, suggesting that heparanase is present systemically and can affect cells and tissues other than the kidney. Heparanase inhibitors may thus protect the kidney and improve its function in transplanted patients.

**Subjects and Methods**

**Patients**

Eligible renal transplant recipients followed at the Tel Aviv Medical Center Transplant Clinic were recruited by their nephrologists. Transplant patients were recruited from attendees at the post-transplant clinic. This convenience sample was developed by recruiting the first 100 patients attending clinic on consecutive days using the following criteria: adult patients aged 18 years and older with stable renal function for at least three months prior to study commencement; no evidence of urinary tract infection or other systemic disease; and no signs of acute rejection or glomerulonephritis. Recruitment was completed within three weeks. All patients approached agreed to participate and signed a formal consent. CKD patients are a convenience sample of attendees at the Nephrology Clinic. Patients attending clinic during a two-week period were approached and asked for an additional test. All 41 patients approached agreed and signed informed consent. Healthy controls were recruited from the clinic staff.

The transplanted patients enrolled were diagnosed as type 1 (n = 21) and type 2 (n = 13) diabetes, adult polycystic kidney disease (n = 17), chronic glomerulonephritis (n = 6), nephrosclerosis (n = 6), focal segmental glomerulosclerosis (n = 5), IgA nephropathy (n = 2), systemic lupus (n = 2), nephritis (n = 2), reflux nephropathy (n = 2), membranoproliferative glomerulonephritis (n = 1), membranous nephropathy (n = 1), fibriillary glomerulonephritis (n = 1), and patients with end stage kidney disease with unknown etiology (n = 21). Ninety-one patients were treated for hypertension. The patients had undergone renal transplantation one to ten years earlier and were treated with a conventional immunosuppressive protocol including corticosteroids, calcineurin inhibitors, and azathioprine or mycophenolate mofetil. Seven patients were treated with cyclosporine, maintaining a trough level between 100–120 ng/ml, one patient was treated with sirolimus, and the other 92 patients were treated with tacrolimus, maintaining trough levels between 4–8 ng/ml.

CKD patients enrolled included type 1 and type 2 diabetes (1 and 20 patients, respectively), atherosclerotic vascular disease (n = 6), hypertension (n = 10), nephrolithiasis (n = 2), focal segmental glomerulosclerosis (n = 1), and systemic lupus erythematosus (n = 1).

Morning blood was drawn for biochemistry, complete blood count and heparanase content. Fresh morning urine samples were obtained for measurements of protein, albumin, creatinine and heparanase. All blood and urine samples for heparanase assay were placed immediately on ice; plasma was separated by centrifugation (5 min, 1200 g, 4°C), and samples were kept at −70°C until analyzed. All patients signed informed consent to participate in the study, which was approved by the Tel Aviv Medical Center Committee for Studies in Human Beings.

**Laboratory measurements**

Blood and urine chemistry, including creatinine, protein, and albumin levels were determined using Advia 1650 equipment (Siemens). Blood count was performed by LH Beckman Coulter. Estimated glomerular filtration rate (eGFR) was determined by the abbreviated four-variable Modification of Diet in Renal Disease (MDRD) equation [26]. Urinary protein and urinary albumin levels are presented as milligram protein or albumin per gram creatinine.

**Heparanase determination**

Heparanase levels were determined according to a previously described ELISA method [25,27,28]. Briefly, wells of microtiter plates were coated (18 h, 4°C) with 2 μg/ml 1E1 anti-heparanase monoclonal antibody in 50 μl of coating buffer (0.05 M Na2CO3, 0.05 M NaHCO3, pH 9.6) and were then blocked with 1% BSA in PBS for 1 h at 37°C. Samples (200 μl) were loaded in duplicates and incubated for 2 h at room temperature, followed by the addition of 100 μl anti-heparanase polyclonal antibody 1453 (1 μg/ml) for additional 2 h at room temperature. HRP-conjugated goat anti-rabbit IgG (Jackson ImmunoResearch, West Grove, PA; 1:20,000) in blocking buffer was then added (1 h, room temperature) and the reaction was visualized by the addition of 100 μl chromogenic substrate (TMB) for 30 min. The reaction was stopped with 100 μl H2SO4 and absorbance at 450 nm was measured with reduction at 630 nm using ELISA plate reader. Plates were washed (×5) with washing buffer (PBS, pH 7.4, containing 0.1% (v/v) Tween 20) after each step. As a reference for quantification, a standard curve was established by a serial dilution of recombinant active heparanase enzyme (25 ng/ml–390 pg/ml), as described [25,27,28]. Urine heparanase levels are expressed as nano gram heparanase per gram of urinary creatinine.

**Statistical Methods**

**Data analysis**

Data analysis was carried out using SPSS version 11.0 statistical analysis software (SPSS Inc., Chicago, IL, USA). Continuous variables are reported as mean ± standard deviation. Variables with distributions significantly deviating from normal are described in addition as median (min-max). Distributions of continuous variables were assessed for normality using the Kolmogorov-Smirnov test (cut off at p = 0.01). One-way analysis of variance (ANOVA) or the Kruskal-Wallis test were used to compare continuous variables across patient category (transplant-recipient, CKD or control), followed post hoc by Bonferroni’s pair wise analysis or the Mann-Whitney U-test, as appropriate. Associations between continuous variables were determined by calculating the Pearson’s or Spearman’s rho correlation coefficients. In transplant patients, eGFR was modeled using multiple linear regression analysis. The most parsimonious model was achieved using a forward approach, with a probability of F at 0.05 for entry and 0.1 for removal. In transplant patients, eGFR was modeled using multiple linear regression analysis. The most parsimonious model was achieved using a backwards approach, with a probability of F at 0.05 for entry and 0.1 for removal. All tests are two-sided and considered significant at p<0.05.
Results

Clinical parameters

We applied an ELISA method to determine heparanase levels in plasma and urine of patients with CKD and patients who underwent kidney transplantation compared to control healthy volunteers. Clinical and demographic description of recruited patients is shown in Table 1. Notably, the demographic characteristics of the patients recruited for the study mirrored the transplant population (n = 237) in terms of gender (38% females), age (52.9 ± 12.9 years), and serum creatinine (1.62 ± 0.6 mg/dl). The study group therefore highly represents kidney transplant patients at the Tel Aviv Medical Center.

Urinary albumin/creatinine levels were strikingly increased in CKD, and to a lesser extent in transplanted patients (median values of 13.1, 281.1, and 23.3 mg/gr for control, CKD and transplanted patients, respectively; Table 1). A similar trend was noted for urinary protein/creatinine levels (69.7, 585.1, 195.1 mg/gr in average for control, CKD, and transplanted patients, respectively; Table 1). The levels of serum albumin, hemoglobin and eGFR were decreased in CKD patients but were higher in patients following kidney transplantation (Table 1). An inverse association between eGFR and proteinuria (p = 0.005), and between eGFR and albuminuria (p = 0.027) was noted in CKD patients, as expected. Hemoglobin was significantly associated with eGFR (r = 0.293, p = 0.004, Table 1) likely since a healthier allograft produces more erythropoietin, altogether indicating that the transplanted kidney is functioning.

Heparanase elevation in CKD and transplanted patients

Heparanase/creatinine levels were elevated three- and four-fold in the urine of CKD and transplanted patients (307.2±95, 950±155, and 1008±134 ng heparanase/gr creatinine in average for control, CKD, and transplanted patients, respectively; Fig. 1A, Table 1), an elevation that is highly significant (p<0.0001 for control vs. CKD and control vs. transplanted patients; Fig. 1C, Table 1). Similar elevation of urine heparanase in CKD and transplanted patients is found once median values are plotted (Fig. 1B). Elevation of heparanase, albeit lower in magnitude, was quantified also in the plasma of CKD and transplanted patients (71.7±22, 136.9±24, and 193.9±73 pg/ml in average for control, CKD and transplanted patients, respectively; Fig. 1C, Table 1). Plasma heparanase is increased in CKD patients but decreased to control levels following kidney transplantation (49, 117, and 24 pg heparanase/gr creatinine for control, CKD, and transplanted patients, respectively, Fig. 1D). A highly significant association (p<0.01) was found between urine and plasma heparanase levels in transplanted patients (Table 2), suggesting that heparanase is present systemically and can affect cells and tissues other than the kidney. No such association was found in CKD patients (Table 2).

We next examined association of plasma and urine heparanase levels with clinical parameters. In transplanted patients, urine heparanase/creatinine was significantly associated with urine protein/creatinine (p<0.006; Table 2), and significantly inversely associated with serum albumin (p<0.02; Table 2), suggesting a causal effect of heparanase in the development of proteinuria and hypoalbuminemia. Notably, an inverse association was found between urine heparanase/creatinine and eGFR (p = 0.03; Table 2; Fig. 2). Moreover, urine heparanase/creatinine positively associated with the time (years) since transplantation (r = 0.313, p = 0.002; Table2), suggesting that elevated heparanase levels may lead to dysfunction of the grafted kidney. Notably, both urine albumin/creatinine and urine protein/creatinine ratios were associated with urinary heparanase/creatinine in CKD patients (p = 0.003, p = 0.001, respectively; Table 2).

The association between log transformed urinary heparanase/creatinine and eGFR was modeled in a linear regression analysis. In addition to log transformed urinary heparanase/creatinine ratio, the variables age, years since transplantation, the urinary protein/creatinine ratio as well as interaction terms were included. The final model, which included only log transformed urinary heparanase/creatinine ratio, was significant (beta = −7.9, 95% CI −14.6−−1.3, p = 0.02), but explained only 6% of the variability in eGFR. Similarly, log transformed urinary protein/creatinine was modeled using log transformed urinary heparanase/creatinine ratio as well as age, years since transplantation, eGFR and interaction terms. In the final model, also arrived at using a

Table 1. Characteristics of study population by diagnostic group.

| Parameter                        | Controls (n = 18) | CKD (n = 41) | Transplant (n = 100) | p-value* |
|----------------------------------|------------------|-------------|----------------------|----------|
| Age (year)                       | 46.1±10.6        | 73.7±13.2   | 51.2±12              |          |
| Sex (% female)                   | 44               | 32          | 35                   |          |
| eGFR (ml/min)b                   | 75.7±2.7         | 30±2.2      | 53.7±1.7             | <0.0001  |
| Serum creatinine (mg/dL)         | 1.0±0.1          | 2.6±0.1     | 1.4±0.1              | <0.0001  |
| Urinary albumin/creatinine (mg/gr; median) | 13.1 (7–24) | 281.1 (11–4674) | 23.3 (2–13978) | 0.001 |
| Urinary protein/creatinine (mg/gr; median) | 69.7 (40–140) | 585.1 (110–7460) | 195.1 (50–5820) | 0.001 |
| Serum albumin (g/L)              | 44.7±1           | 40.2±0.6    | 43.4±3.4             | 0.001    |
| Serum protein (g/L)              | 724±2            | 70.4±0.8    | 71.1±0.5             | 0.2      |
| Hemoglobin (g/dL)                | 143±6.0          | 119±0.2     | 136±0.2              | <0.0001  |
| Plasma heparanase (pg/ml)        | 717±22           | 1369±24     | 193.9±73             | <0.0001  |
| Urinary heparanase/creatinine (ng/gr; average, median) | 307.2±95.1 | 130.3 (16–1520) | 950.3±155.9 | 0.001 |

Data is presented as mean±S.D and/or as median values (min-max).

*One-way analysis of variance (ANOVA) or the Kruskal-Wallis test were used to compare continuous variables across patient category (control, CKD and transplanted), followed post hoc by Bonferroni’s pair wise analysis or the Mann-Whitney U-test, as appropriate.

**Estimated glomerular filtration rate (eGFR) was determined by the abbreviated Modification of Diet in Renal Disease (MDRD) equation [26].

doi:10.1371/journal.pone.0044076.t001
stepwise, backward approach, only log transformed urinary heparanase/creatinine ratio remained (Fig. 3). Again, while the model was significant (beta = 0.27, 95% CI 0.1–0.5, p = 0.003), it explained only 9% of the variability in log transformed urinary protein/creatinine. Convergence was not reached for a model of urinary albumin/creatinine. In contrast, no association was found between urine heparanase/creatinine ratio and eGFR in CKD patients, suggesting that such a correlation observed in transplant patients is not solely due to kidney dysfunction or proteinuria. Also, there was no association between urine heparanase/creatinine and plasma heparanase in CKD patients.

Table 2. Association between log transformed urine heparanase/creatinine levels and studied parameters in transplanted (n = 100) and CKD (n = 41) patients.

| Parameter                              | CKD                           | Transplant                  |
|----------------------------------------|-------------------------------|-----------------------------|
|                                        | correlation coefficient | p value | correlation coefficient | p value |
| Age                                    | 0.118                         | 0.463            | −0.016                  | 0.883   |
| Years since transplantation            |                               | 0.313            |                         | 0.002   |
| Plasma heparanase                      | 0.1                           | 0.54              | 0.261                   | 0.01    |
| eGFRb                                  | −0.01                         | 0.936            | −0.223                  | 0.03    |
| Urinary protein/creatinine             | 0.459                         | 0.001            | 0.284                   | 0.006   |
| Urinary albumin/creatinine             | 0.513                         | 0.003            | 0.147                   | 0.3     |
| Serum albumin                          | −0.263                        | 0.097            | −0.243                  | 0.02    |

*aPearson’s or Spearman’s correlation coefficients are presented within CKD and transplant groups, respectively.

*bEstimated glomerular filtration rate (eGFR) was determined by the abbreviated Modification of Diet in Renal Disease (MDRD) equation [26].

doi:10.1371/journal.pone.0044076.t002
Discussion

Kidney transplantation is the treatment of choice for end-stage renal disease, conferring the highest survival benefit among the different renal replacement therapies. However, many transplant-d patients develop proteinuria and chronic allograft dysfunction. The exact mechanism(s) leading to long-term graft loss are unclear. Both immune-dependent and -independent factors are thought to play a role [29]. Despite improved immunosuppressive regimens, chronic allograft nephropathy (CAN) remains the main cause of graft loss. CAN is associated with histologic evidence of fibrosis, proteinuria, and a progressive decrease in eGFR [30]. Proteinuria post transplant can be either secondary to CAN or to recurrent glomerulopathy, or diabetic nephropathy, and we cannot rule out the possibility that some patients in this study may exhibit an additional glomerulopathy.

The present study evaluated heparanase as a potential novel player associated with renal dysfunction in renal transplant recipients. We examined plasma and urine heparanase levels in renal transplant recipients and CKD patients and addressed relevant clinical correlations. Notably, in transplanted patients urinary heparanase/creatinine ratio was significantly, inversely associated with eGFR (Table 2, Fig. 2). Moreover, urine heparanase/creatinine ratio positively associated with the years post transplantation. In contrast, no association was found between urine heparanase/creatinine ratio and eGFR in CKD patients, suggesting that this correlation observed in transplanted patients is not solely due to kidney dysfunction or proteinuria.

Importantly, we found that urinary heparanase levels correlate significantly with proteinuria in CKD and transplanted patients (Table 2), suggesting a role for heparanase in kidney dysfunction, in agreement with previous pre-clinical and clinical studies [4,5]. Increased urinary heparanase has also been implicated in several human proteinuric diseases such as diabetes, minimal change disease, membranous nephropathy and IgA nephropathy [5,31]. A loss of GBM and tubular HS was noted in kidney biopsies from patients with overt diabetes, accompanied by increased expression of heparanase [15,16]. Development of proteinuria and CKD may be associated with heparanase-mediated damage to the glomerular filtration barrier. It has been well established in CKD that the degree of proteinuria strongly relates to kidney survival. This observation has also been demonstrated in renal transplant recipients where there is a strong association between proteinuria and reduced kidney allograft survival [32]. This relationship extends also to lower levels of proteinuria that are not associated with glomerular pathology. Seventy-seven percent of allografts lost within the first 5 years post-transplant had proteinuria at 1 year [33]. This study and others demonstrate that proteinuria provides an independent prognostic factor for renal graft survival beyond histologic findings. Collectively, these results suggest that heparanase may play a significant role in the pathogenesis of proteinuria and kidney dysfunction.

In addition, urinary heparanase correlated significantly with plasma heparanase levels in transplanted (p = 0.01), but not in CKD (p = 0.54; Table 2) patients. Such a systemic presence of heparanase may lead to the damage of cells and tissues alongside the kidney. In the transplanted kidney, chronic endothelial injury is characterized by the presence of disruption of lamina elastica interna, inflammatory cells in the fibrotic intima and proliferation of myofibroblasts in the intima, indicative of chronic T-cell-mediated rejection [30]. Continuous exposure of the vascular endothelium to heparanase may lead to a severe outcome. It has been shown, for example, that heparanase over-expression leads to arterial thickening and reduced mechanical strength [34]. Moreover, heparanase over-expression enhances neointimal thickening due to increased proliferation and recruitment of macrophages following stent implementation [34], whereas neutralizing anti-heparanase antibodies reduced neointima formation in a rat carotid balloon injury model [35].

Accumulating evidence suggests that heparanase functions also as a pro-coagulation mediator, enhancing expression of tissue factor and generation of factor Xa, two critical components in blood coagulation [36–38] thus providing another mode by which heparanase affects the vasculature. Continuous exposure to high levels of heparanase in the circulation may thus contribute to the development of CKD-, and transplantation-associated vasculopathies.

We have reported recently that heparanase levels are elevated in the urine and plasma of diabetic patients [31]. In diabetic patients, heparanase levels were significantly reduced following kidney transplantation implying that heparanase originates primarily
have developed an inflammatory condition to various extents. Pro-inflammatory processes contribute to adverse clinical outcomes [43]. It should be noted that the patients enrolled in this study had been transplanted one year prior to the enrollment and were likely to have developed an inflammatory condition to various extents. Pro-inflammatory state and consequently increased heparanase levels may be associated with the development of proteinuria and decreased renal function following transplantation. Studies examining the association between kidney inflammation and heparanase levels are currently in progress.

Experimental evidence supports the idea that heparanase-inhibiting heparin-derived agents and glycosaminoglycans favorably affect primary and secondary renal diseases, likely via inhibition of heparanase enzymatic activity. While a number of clinical studies have addressed the effect of these agents (i.e., sulodexide) in microalbuminuric and macroalbuminuric diabetic patients, very few have investigated their activity in non diabetic renal conditions [44,45]. The present study implicates heparanase in the etiology of chronic renal allograft nephropathy, both as a circulating marker and as a drug target. Despite the introduction of novel drugs and the associated reduction in acute rejection rates, there has been no improvement in long-term allograft survival over the last decade. The newly described association between heparanase, proteinuria and decreased renal function is hoped to pave the way for new therapeutic options aimed at attenuating chronic renal allograft nephropathy, leading to improved graft survival and patient outcome.

**Author Contributions**

Conceived and designed the experiments: IV TW NI IS. Performed the experiments: IS. Analyzed the data: IS TW NI IV. Contributed reagents/materials/analysis tools: TW AA MB DS RB RN. Wrote the paper: NI TW IV IS.

**References**

1. Raats CJ, Van Den Born J, Berden JH (2000) Glomerular heparan sulfate alterations: mechanisms and relevance for proteinuria. Kidney Int 57: 385–400.
2. Bjornsson Granquist A, Ehefor K, Saleem MA, Mathieson PW, Haraldsson B, et al. (2006) Podocyte proteoglycan synthesis is involved in the development of nephrotic syndrome. Am J Physiol Renal Physiol 291: F722–730.
3. Kanwar YS, Danesh FR, Chugh SS (2007) Contribution of proteoglycans towards the integrated functions of renal glomerular capillaries: a historical perspective. Am J Pathol 171: 9–13.
4. Szmyczek M, Kuznier J, Klinger M (2010) The role of heparanase in diseases of diabetes and CKD conditions. In diabetes, urine heparanase is involved in the pathogenesis of proteinuria as a result of glomerulonephritis. J Am Soc Nephrol 15: 68–78.
5. van den Hoven MJ, Rops AL, Vlodavsky I, Levitan V, Berden JH, et al. (2007) Heparanase in glomerular diseases. Kidney Int 72: 543–548.
6. Kanwar YS, Linker A, Farquier MG (1980) Increased permeability of the glomerular basement membrane to ferritin after removal of glycosaminoglycans (heparan sulfate) by enzyme digestion. J Cell Biol 86: 688–693.
7. Raats CJ, Luca ME, Bakker MA, Van Der Wal A, Heeringa P, et al. (1999) Reduction in glomerular heparan sulfate correlates with complement deposition and albuminuria in active Heymann nephritis. J Am Soc Nephrol 10: 1689–1699.
8. Rops AL, van der Vlag J, Lensf, JF, Wijnhoven TJ, van den Heuel LP, et al. (2004) Heparan sulfate proteoglycans in glomerular inflammation. Kidney Int 63: 768–763.
9. van den Born J, van den Heuel LP, Bakker MA, Veerakamp JH, Assmann KJ, et al. (1993) Distribution of GBM heparan sulfate proteoglycan core protein and side chains in human glomerular diseases. Kidney Int 43: 454–463.
10. van den Born J, van den Heuel LP, Bakker MA, Veerakamp JH, Assmann KJ, et al. (1992) A monoclonal antibody against GBM heparan sulfate induces an acute selective proteinuria in rats. Kidney Int 41: 115–123.
11. Holt RC, Webb NJ, Ralph S, Davies J, Short CD, et al. (2005) Heparanase activity is downregulated in children with steroid-sensitive nephrotic syndrome. J Am Soc Nephrol 16: 2133–2139.
12. Katz A, Van-Dijk DJ, Aingorn H, Erman A, Davies M, et al. (2002) Involvement of human heparanase in the pathogenesis of diabetic nephropathy. Isr Med Assoc J 4: 996–1002.
13. Levidiotis V, Freeman C, Tikellis C, Cooper ME, Power DA (2004) Heparanase is involved in the pathogenesis of proteinuria as a result of glomerulonephritis. J Am Soc Nephrol 15: 68–78.
14. Levidiotis V, Kanellis J, Irinio FL, Power DA (2001) Increased expression of heparanase in purpuric aminoacidosse nephrosis. Kidney Int 60: 1287–1296.
15. van den Hoven MJ, Rops AL, Bakker MA, Aten J, Rutjes N, et al. (2006) Increased expression of heparanase in overt diabetic nephropathy. Kidney Int 70: 2100–2108.
16. Wijnhoven TJ, van den Hoven MJ, Ding H, van Kuppevelt TH, van der Vlag J, et al. (2008) Heparanase induces a differential loss of heparan sulfate domains in overt diabetic nephropathy. Diabetologia 51: 372–382.
17. Barash U, Cohen-Kaplan V, Dowek I, Sanderson RD, Ilan N, et al. (2010) Proteoglycans in health and disease: new concepts for heparanase function in tumor progression and metastasis. FEBS J 277: 2580–2593.
18. Levy-Adam F, Ilan N, Vlodavsky I (2010) Tumorigenic and adhesive properties of heparanase. Semin Cancer Biol 20: 153–160.
19. Vlodavsky I, Ilan N, Naggi A, Casa B (2007) Heparanase: structure, biological functions, and inhibition by heparin-derived mimetics of heparan sulfate. Curr Pharm Des 13: 2057–2073.
20. Vreys V, David G (2007) Mammalian heparanase: is it our friend? J Cell Mol Med 11: 427–452.
21. Levidiotis V, Freeman C, Pudler M, Martinello P, Creese B, et al. (2004) A synthetic heparanase inhibitor reduces proteinuria in passve Heymann nephritis. J Am Soc Nephrol 15: 2819–2824.
22. Levidiotis V, Freeman C, Tikellis C, Cooper ME, Power DA (2005) Heparanase inhibition reduces proteinuria in a model of accelerated anti-glomerular basement membrane antibody disease. Nephrol (Carlton) 10: 167–173.
23. Kramer A, van den Hoven M, Rops A, Wijnhoven T, van den Heuel L, et al. (2006) Induction of glomerular heparanase expression in rats with adriamycin nephropathy is regulated by reactive oxygen species and the renin-angiotensin system. J Am Soc Nephrol 17: 2513–2520.
24. Zeharia E, Metzger S, Chajek-Shaul T, Aungorn H, Ekaris M, et al. (2004) Transgenic expression of mammalian heparanase uncovers physiological functions of heparan sulfate in tissue morphogenesis, vascularization, and feeding behavior. FASEB J 18: 252–263.
25. Shtatla LP, Pode D, Peretz T, Ilan N, Vlodavsky I, et al. (2000) Clinical significance of urine heparanase in bladder cancer progression. Neoplasia 10: 125–130.
26. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, et al. (1999) A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 130: 461–470.
27. Shafat I, Ben-Barak A, Postovsky S, Elhadad R, Ilan N, et al. (2007) Heparanase levels are elevated in the plasma of pediatric cancer patients and correlate with response to anticancer treatment. Neoplasia 9: 909–916.
28. Shafat I, Zeharia E, Nunan B, Nadir Y, Nakhol F, et al. (2006) An ELISA method for the detection and quantification of human heparanase. Biochem Biophys Res Commun 341: 958–963.
29. Massy ZA, Guijarro C, Wiederkehr MR, Ma JZ, Kasieke BL (1996) Chronic renal allograft rejection: immunologic and nonimmunologic risk factors. Kidney Int 49: 518–524.

30. Najafian B, Kasieke BL (2008) Chronic allograft nephropathy. Curr Opin Nephrol Hypertens 17: 149–155.

31. Shafat I, Ban N, Zoabi S, Vlodavsky I, Nakhoul F (2011) Heparanase levels are elevated in the urine and plasma of type 2 diabetes patients and associate with blood glucose levels. PLoS One 6: e17312.

32. Amer H, Costo FG (2009) Significance and management of proteinuria in kidney transplant recipients. J Am Soc Nephrol 20: 2490–2492.

33. Amer H, Fuller ME, Myslak M, Morales P, Kremers WK, et al. (2007) Proteinuria after kidney transplantation, relationship to allograft histology and survival. Am J Transplant 7: 2748–2756.

34. Baker AB, Groothuis A, Jonas M, Ettenson DS, Shazly T, et al. (2009) Heparanase alters arterial structure, mechanics, and repair following endovascular stenting in mice. Circ Res 104: 380–387.

35. Myler HA, Lipke EA, Rice EE, West JL (2006) Novel heparanase-inhibiting antibody reduces neointima formation. J Biochem (Tokyo) 139: 339–345.

36. Nadir Y, Brenner B, Fox I, Shafat I, Attias J, et al. (2010) Heparanase enhances factor Xa generation in the presence of tissue-factor and factor VIIa. Haematologica 95: 1927–1934.

37. Nadir Y, Brenner B, Ginge-Velinski S, Levy-Adam F, Ban N, et al. (2008) Heparanase induces tissue factor pathway inhibitor expression and extracellular accumulation in endothelial and tumor cells. Thromb Haemost 99: 133–141.

38. Nadir Y, Brenner B, Zetser A, Ban N, Shafat I, et al. (2008) Heparanase induces tissue factor expression in vascular endothelial and cancer cells. J Thromb Haemost 4: 2443–2451.

39. Maschiner JB, Someren M, Rao G, Pesce CE, Baldwin D Jr, et al. (2005) Heparanase–1 gene expression and regulation by high glucose in renal epithelial cells: a potential role in the pathogenesis of proteinuria in diabetic patients. Diabetes 54: 2172–2178.

40. Wang F, Wang Y, Kim MS, Purhanveetil P, Ghosh S, et al. (2018) Glucose-induced endothelial heparanase secretion requires cortical and stress actin reorganization. Cardiovasc Res 87: 127–136.

41. Shafat I, Vlodavsky I, Ban N (2006) Characterization of mechanisms involved in secretion of active heparanase. J Biol Chem 281: 23004–23011.

42. Vlodavsky I, Eldor A, Haimovitz-Friedman A, Matzner Y, Ishai-Michaeli R, et al. (1992) Expression of heparanase by platelets and circulating cells of the immune system: possible involvement in diapedesis and extravasation. Invasion Metastasis 11: 112–127.

43. Yilmaz MI, Stenvinkel P, Sonmez A, Saglam M, Yaman H, et al. (2011) Vascular health, systemic inflammation and progressive reduction in kidney function; clinical determinants and impact on cardiovascular outcomes. Nephrol Dial Transplant. In Press.

44. Lewis KD, Robinson WA, Milburn MJ, Powell A, Price TJ, et al. (2008) A phase II study of the heparanase inhibitor PI-88 in patients with advanced melanoma. Invest New Drugs 26: 89–94.

45. Wijnhoven TJ, Lensen JF, Rops AL, McCarthy KJ, van der Vlag J, et al. (2007) Anti-proteomic effects of glycosaminoglycan-based drugs. Curr Opin Mol Ther 9: 364–377.